Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

June 30, 2004

Primary Completion Date

December 31, 2006

Study Completion Date

May 31, 2007

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG

TRAIL-R1 mAb (TRM-1; HGS-ETR1)

Trial Locations (7)

Memorial Sloan Kettering, New York

Roswell Park Cancer Institute, Buffalo

Fox Chase Cancer Center, Philadelphia

Sarah Cannon Research Institute, Nashville

Mayo Clinic, Rochester

University of Nebraska Medical Center, Omaha

MD Anderson Cancer Center, Houston